TAK 906

Drug Profile

TAK 906

Alternative Names: TAK 906 Maleate; TAK906

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda Oncology
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastroparesis

Most Recent Events

  • 05 Jun 2018 Takeda plans a phase II trial for Gastroparesis in September 2018 (NCT03544229)
  • 10 Mar 2018 Millennium Pharmaceuticals completes a phase II trial for Gastroparesis in USA (PO) (NCT03268941)
  • 24 Nov 2017 Phase-II clinical trials in Gastroparesis in USA (PO) (3285061; Takeda Q2 report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top